<DOC>
	<DOCNO>NCT00044733</DOCNO>
	<brief_summary>The primary objective study evaluate safety gemtuzumab ozogamicin relapse CD33-positive AML patient receive HSCT . If MTD dose reach , 9 mg/m2 maximum test dose . A secondary objective ass efficacy term number patient attain complete ( CR ) morphological ( CRp ) remission .</brief_summary>
	<brief_title>Study Evaluating Gemtuzumab Ozogamicin Acute Myelogenous Leukemia After Stem Cell Transplant</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Inclusion Criteria Patients CD33+ AML experience relapse autologous allogeneic HSCT . Flow cytometry , perform study site , must demonstrate patient AML CD33 positive , base local laboratory criterion ( Patients history MDS pretransplant eligible proportion myeloblast marrow aspirate exceeds 5 % time evaluation Gemtuzumab Ozogamicin treatment ) The patient must great equal 60 day postHCST Patients age may enter study Exclusion Criteria Peripheral white blood count ( WBC ) great equal 30,000/uL time initial Gemtuzumab Ozogamicin administration . ( In order reduce peripheral blood count , patient may treat Hydroxyurea . Hydroxyurea must discontinue 24 hour prior Gemtuzumab Ozogamicin administration . ) Known active central nervous system ( CNS ) testicular leukemia time study entry . Prior therapy antiCD33 antibody .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Stem Cell Transplant</keyword>
</DOC>